Drug discovery in Parkinson's disease: update and developments in the use of cellular models

References

• Wakabayashi K, Mori F, Takahashi H. Progression patterns of neuronal loss and Lewy body pathology in the substantia nigra in Parkinson’s disease. Parkinsonism RelatDisord. 2006;12 Suppl 2:S92–S98.
   Google Scholar
• De Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004;63:1240–1244.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–386.
   PubMed Web of Science ®Google Scholar
• Cotzias MH, Van Woert, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276:374–379.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.
   PubMed Web of Science ®Google Scholar
• Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337–341.
   PubMed Web of Science ®Google Scholar
• Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson’s disease. Parkinsonism Relat Disord. 2010;16:79–84.
   PubMed Web of Science ®Google Scholar
• Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov. 2004;3:451–456.
   PubMed Web of Science ®Google Scholar
• Lou K, de Rond M. The ‘ not invented here’ myth. Nat Rev Drug Discov. 2006;5:451–452.
   PubMed Web of Science ®Google Scholar
• Muller T. New small molecules for the treatment of Parkinson’s disease. Expert Opin Investig Drugs. 2010;19:1077–1086.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Damier P, Hicking C. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22:179–186.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185.
   PubMed Web of Science ®Google Scholar
• de Vries HE, Witte M, Hondius D, et al. Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radic Biol Med. 2008;45:1375–1383.
   PubMed Web of Science ®Google Scholar
• Nolan GP. What’s wrong with drug screening today. Nat Chem Biol. 2007;3:187–191.
   PubMed Web of Science ®Google Scholar
• Young DW, Bender A, Hoyt J, et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol. 2008;4:59–68.
   PubMed Web of Science ®Google Scholar
• Ma P Zemmel R. Value of novelty? Nat Rev Drug Discov. 2002;1:571–572.
   Web of Science ®Google Scholar
• Rezak M. Current pharmacotherapeutic treatment options in Parkinson’s disease. Dis Mon. 2007;53:214–222.
   PubMedGoogle Scholar
• Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607.
   PubMed Web of Science ®Google Scholar
• Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44:595–600.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha- synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–2047.
   PubMed Web of Science ®Google Scholar
• Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–608.
   PubMed Web of Science ®Google Scholar
• Bonifati V Rizzu P van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256–259.
   Web of Science ®Google Scholar
• Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304:1158–1160.
   PubMed Web of Science ®Google Scholar
• Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184–1191.
   PubMed Web of Science ®Google Scholar
• Wood-Kaczmar A, Gandhi S, Wood NW. Understanding the molecular causes of Parkinson’s disease. Trends Mol Med. 2006;12:521–528.
   PubMed Web of Science ®Google Scholar
• Malkus KA, Tsika E, Ischiropoulos H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson’s disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener. 2009;4:24.
   PubMed Web of Science ®Google Scholar
• Lewy FH. Paralysis agitans. I. Pathologische anatomie. Handbuch der Neurologie. [Paralysis agitans. I. Pathological anatomy. Handbook of Neurology.] Berlin: Springer; 1912:920–933.
   Google Scholar
• Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990;54:823–827.
   PubMed Web of Science ®Google Scholar
• Finkbeiner S, Cuervo AM, Morimoto RI, Muchowski PJ. Disease-modifying pathways in neurodegeneration. J Neurosci. 2006;26:10349–10357.
   PubMed Web of Science ®Google Scholar
• Lim KL, Ng CH. Genetic models of Parkinson disease. Biochim Biophys Acta. 2009;1792:604–615.
   PubMed Web of Science ®Google Scholar
• Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson’s disease. Neuro Rx. 2005;2:484–494.
   Google Scholar
• Fornai F, Schlüter OM, Lenzi P et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin- proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A. 2005;102:3413–3418.
   PubMed Web of Science ®Google Scholar
• Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nat Med. 2010;16:998–1000.
   PubMed Web of Science ®Google Scholar
• Lin X, Parisiadou L, Gu XL, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease- related mutant alpha-synuclein. Neuron. 2009;64:807–827.
   PubMed Web of Science ®Google Scholar
• Yoon IS, Au Q, Barber JR, Ng SC, Zhang B. Development of a high- throughput screening assay for cytoprotective agents in rotenone- induced cell death. Anal Biochem. 2010;407:205–210.
   Web of Science ®Google Scholar
• Falkenburger BH, Schulz JB. Limitations of cellular models in Parkinson’s disease research. J Neural Transm Suppl. 2006;70:261–268.
   Google Scholar
• Marx FP, Holzmann C, Strauss KM, et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson’s disease. Hum Mol Genet. 2003;12:1223–1231.
   PubMed Web of Science ®Google Scholar
• Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2004;2:e362.
   PubMed Web of Science ®Google Scholar
• Zhou W, Freed CR. Tyrosine-to-cysteine modification of human alpha- synuclein enhances protein aggregation and cellular toxicity. J Biol Chem. 2004;279:10128–10135.
   PubMed Web of Science ®Google Scholar
• Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 2000;866:33–43.
   Web of Science ®Google Scholar
• Yang F, Yang YP, Mao CJ, et al. Role of autophagy and proteasome degradation pathways in apoptosis of PC12 cells overexpressing human alpha-synuclein. Neurosci Lett. 2009;454:203–208.
   Web of Science ®Google Scholar
• Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem. 2002;277:38884–38894.
   PubMed Web of Science ®Google Scholar
• Eglen RM, Gilchrist A, Reisine T. The use of immortalized cell lines in GPCR screening: the good, bad and ugly. Comb Chem High-throughput Screen. 2008;11:560–565.
   PubMed Web of Science ®Google Scholar
• Do JH, Kim IS, Park TK, Choi DK. Genome-wide examination of chromosomal aberrations in neuroblastoma SH-SY5Y cells by array-based comparative genomic hybridization. Mol Cells. 2007;24:105–112.
   Web of Science ®Google Scholar
• Kenakin TP. New eyes to see texture in ligand efficacy. Nat Methods. 2005;2:163–164.
   Web of Science ®Google Scholar
• Kola I, Landis H. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–715.
   PubMed Web of Science ®Google Scholar
• Eglen RM, Gilchrist A, Reisine T. An overview of drug screening using primary and embryonic stem cells. Comb Chem High-throughput Screen. 2008;11:566–572.
   PubMed Web of Science ®Google Scholar
• Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem. 1997;69:1398–1408.
   PubMed Web of Science ®Google Scholar
• Heyer EJ. Electrophysiological study of mammalian neurons from ventral mesencephalon grown in primary dissociated cell culture. Brain Res. 1984;310:142–148.
   Web of Science ®Google Scholar
• Chiodo LA, Bunney BS. Population response of midbrain dopaminergic neurons to neuroleptics: further studies on time course and nondop- aminergic neuronal influences. J Neurosci. 1987;7:629–633.
   PubMed Web of Science ®Google Scholar
• Rayport S, Sulzer D, Shi WX. Identified postnatal mesolimbic dopamine neurons in culture: morphology and electrophysiology. J Neurosci. 1992;12:4264–4280.
   Web of Science ®Google Scholar
• McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci. 2002;16:2136–2148.
   PubMed Web of Science ®Google Scholar
• Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron. 2003;37:735–749.
   PubMed Web of Science ®Google Scholar
• Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med. 2001;344:710–719.
   PubMed Web of Science ®Google Scholar
• Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501–503.
   PubMed Web of Science ®Google Scholar
• Zhou W, Schaack J, Zawada WM, Freed CR. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 2002;926:42–50.
   Web of Science ®Google Scholar
• McNeish JD. Stem cells as screening tools in drug discovery. Curr Opin Pharmacol. 2007;7:515–520.
   Web of Science ®Google Scholar
• Pouton CW, Haynes JM. Embryonic stem cells as a source of models for drug discovery. Nat Rev Drug Discov. 2007;6:605–616.
   PubMed Web of Science ®Google Scholar
• McNeish J. Embryonic stem cells in drug discovery. Nat Rev Drug Discov. 2004;3:70–80.
   PubMed Web of Science ®Google Scholar
• Lazic SE, Barker RA. The future of cell-based transplantation therapies for neurodegenerative disorders. J Hematother Stem Cell Res. 2003;12:635–642.
   PubMedGoogle Scholar
• Kawasaki H, Suemori H, Mizuseki K, et al. Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity. Proc Natl Acad Sci U S A. 2002;99:1580–1585.
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Mizuseki K, Nishikawa S. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron. 2000;28:31–40.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol. 2000;18:675–679.
   PubMed Web of Science ®Google Scholar
• Raye WS, Tochon-Danguy N, Pouton CW, Haynes JM. Heterogeneous population of dopaminergic neurons derived from mouse embryonic stem cells: preliminary phenotyping based on receptor expression and function. Eur J Neurosci. 2007;25:1961–1970.
   Web of Science ®Google Scholar
• Kim JH, Auerbach JM, Rodriguez-Gomez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature. 2002;418:50–56.
   PubMed Web of Science ®Google Scholar
• Ben-Hur T, Idelson M, Khaner H. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells. 2004;22:1246–1255.
   PubMed Web of Science ®Google Scholar
• Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A. 2002;99:2344–2349.
   PubMed Web of Science ®Google Scholar
• Park CH, Minn YK, Lee JY, et al. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J Neurochem. 2005;92:1265–1276.
   PubMed Web of Science ®Google Scholar
• Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A. 2004;101:12543–12548.
   PubMed Web of Science ®Google Scholar
• Zeng X, Cai J, Chen J, et al. Dopaminergic differentiation of human embryonic stem cells. Stem Cells. 2004;22:925–940.
   PubMed Web of Science ®Google Scholar
• Morizane A, Darsalia V, Guloglu MO. A simple method for large-scale generation of dopamine neurons from human embryonic stem cells. J Neurosci Res. 2010;88:3467–3478.
   Web of Science ®Google Scholar
• Cooper O, Hargus G, Deleidi M, et al. Differentiation of human ES and Parkinson’s disease induced pluripotent stem cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci. 2010;45:258–266.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Roy NS, Keyoung HM, et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med. 2003;9:439–447.
   PubMed Web of Science ®Google Scholar
• Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992;255:1707–1710.
   PubMed Web of Science ®Google Scholar
• Wright LS, Prowse KR, Wallace K, Linskens MH, Svendsen CN. Human progenitor cells isolated from the developing cortex undergo decreased neurogenesis and eventual senescence following expansion in vitro. Exp Cell Res. 2006;312:2107–2120.
   PubMed Web of Science ®Google Scholar
• Kim SU. Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology. 2004;24:159–171.
   PubMed Web of Science ®Google Scholar
• Donato R, Miljan EA, Hines SJ, et al. Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci. 2007;8:36.
   PubMed Web of Science ®Google Scholar
• Wood-Kaczmar A, Gandhi S, Yao Z, et al. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One. 2008;3:e2455.
   PubMed Web of Science ®Google Scholar
• Pruszak J, Sonntag KC, Aung MH, Sanchez-Pernaute R, Isacson O. Markers and methods for cell sorting of human embryonic stem cell- derived neural cell populations. Stem Cells. 2007;25:2257–2268.
   PubMed Web of Science ®Google Scholar
• Li M, Pevny L, Lovell-Badge R, Smith A. Generation of purified neural precursors from embryonic stem cells by lineage selection. Curr Biol. 1998;8:971–974.
   PubMed Web of Science ®Google Scholar
• Zhou W, Lee YM, Guy VC, Freed CR. Embryonic stem cells with GFP knocked into the dopamine transporter yield purified dopamine neurons in vitro and from knock-in mice. Stem Cells. 2009;27:2952–2961.
   PubMed Web of Science ®Google Scholar
• Schneider BL, Seehus CR, Capowski EE, Aebischer P, Zhang SC, Svendsen CN. Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. Hum Mol Genet. 2007;16:651–666.
   Web of Science ®Google Scholar
• Martinat C, Shendelman S, Jonason A, et al. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary Parkinsonism. PLoS Biol. 2004;2:e327.
   PubMed Web of Science ®Google Scholar
• McNeish J, Roach M, Hambor J, et al. High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha- amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors. J Biol Chem. 2010;285:17209–17217.
   PubMed Web of Science ®Google Scholar
• Paquette JA, Kumpf SW, Streck RD, Thomson JJ, Chapin RE, Stedman DB. Assessment of the embryonic stem cell test and application and use in the pharmaceutical industry. Birth Defects Res B Dev Reprod Toxicol. 2008;83:104–111.
   PubMed Web of Science ®Google Scholar
• Seiler A, Visan A, Buesen R, Genschow E, Spielmann H. Improvement of an in vitro stem cell assay for developmental toxicity: the use of molecular endpoints in the embryonic stem cell test. Reprod Toxicol. 2004;18:231–240.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676.
   PubMed Web of Science ®Google Scholar
• Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313–317.
   PubMed Web of Science ®Google Scholar
• Swistowski A, Peng J, Liu Q, et al. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells. 2010;28:1893–1904.
   PubMed Web of Science ®Google Scholar
• Soldner F, Hockemeyer D, Beard C, et al. Parkinson’s disease patient- derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009;136:964–977.
   PubMed Web of Science ®Google Scholar
• Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson’s disease. Proc Natl Acad Sci U S A. 2008;105:5856–5861.
   PubMed Web of Science ®Google Scholar
• Niclis JC, Trounson AO, Dottori M, et al. Human embryonic stem cell models of Huntington disease. Reprod Biomed Online. 2009;19:106–113.
   PubMed Web of Science ®Google Scholar
• Maj MC, Tkachyova I, Patel P, et al. Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. Biochem Biophys Res Commun. 2010;399:331–335.
   Web of Science ®Google Scholar
• Rakovic A, Grünewald A, Seibler P, et al. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet. 2010;19:3124–3137.
   Web of Science ®Google Scholar
• Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877–886.
   PubMed Web of Science ®Google Scholar
• Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson patient- derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA. 2010;107:15921–15926.
   PubMed Web of Science ®Google Scholar
• Grealish S, Jönsson ME, Li M, Kirik D, Björklund A, Thompson LH. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson’s disease. Brain. 2010;133(Pt 2):482–495.
   Google Scholar
• Elsworth JD, Deutch AY, Redmond DE Jr, Sladek JR Jr, Roth RH. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Res. 1990;513:320–324.
   Web of Science ®Google Scholar
• Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990;13:290–296.
   PubMed Web of Science ®Google Scholar
• Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol. 1984;41:856–861.
   PubMedGoogle Scholar
• Nguyen HN, Byers B, Cord B, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011;8:267–280.
   PubMed Web of Science ®Google Scholar
• Hockemeyer D, Soldner F, Beard C, et al. Efficient targeting of expressed and silent genes in human embryonic stem cells and iPSCs using zinc-finger nucleases. Nat Biotechnol. 2009;27:851–857.
   PubMed Web of Science ®Google Scholar
• Zou J, Maeder ML, Mali P, et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell. 2009;5:97–110.
   PubMed Web of Science ®Google Scholar
• Change N, Mercier G, Lucotte G. Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects. Genet Test. 2008;12:333–339.
   Google Scholar
• Laurent LC, Nievergelt CM, Lynch C, et al. Restricted ethnic diversity in human embryonic stem cell lines. Nat Methods. 2010;7:6–7.
   PubMed Web of Science ®Google Scholar
• Carr J, de la Fuente-Fernandez R, Schulzer M, et al. Familial and sporadic Parkinson’s disease usually display the same clinical features. Parkinsonism Relat Disord. 2003;9:201–204.
   PubMed Web of Science ®Google Scholar
• Langston JW. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol. 2006;59:591–596.
   PubMed Web of Science ®Google Scholar
• Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson’s disease. Brain. 2009;132(Pt 11):2947–2957.
   PubMedGoogle Scholar
• Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18:R48–R59.
   PubMed Web of Science ®Google Scholar
• Osafune K, Caron L, Borowiak M, et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol. 2008;26:313–315.
   PubMed Web of Science ®Google Scholar
• Choi KD, Yu J, Smuga-Otto K, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells. 2009;27:559–567.
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007;322:709–720.
   PubMed Web of Science ®Google Scholar
• Barbaric I, Gokhale PJ, Andrews PW. High-content screening of small compounds on human embryonic stem cells. Biochem Soc Trans. 2010;38:1046–1050.
   Web of Science ®Google Scholar
• Jain S, Heutink P. From single genes to gene networks: high- throughput-high-content screening for neurological disease. Neuron. 2010;68:207–217.
   Web of Science ®Google Scholar
• Daub A, Sharma P, Finkbeiner S. High-content screening of primary neurons: ready for prime time. Curr Opin Neurobiol. 2009;19:537–543.
   PubMed Web of Science ®Google Scholar
• Jones TR, Carpenter AE, Lamprecht MR, et al. Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A. 2009;106:1826–1831.
   PubMed Web of Science ®Google Scholar
• Arrasate M, Finkbeiner S. Automated microscope system for determining factors that predict neuronal fate. Proc Natl Acad Sci U S A. 2005;102:3840–3845.
   PubMed Web of Science ®Google Scholar
• Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805–810.
   PubMed Web of Science ®Google Scholar
• Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, Finkbeiner S. Quantitative relationships cbetween huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into Huntington’s disease molecular pathogenesis. J Neurosci. 2010;30:10541–10550.
   PubMed Web of Science ®Google Scholar
• Mitra S, Tsvetkov AS, Finkbeiner S. Single neuron ubiquitin- proteasome dynamics accompanying inclusion body formation in Huntington disease. J Biol Chem. 2009;284:4398–4403.
   PubMed Web of Science ®Google Scholar
• Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30:639–649.
   PubMed Web of Science ®Google Scholar
• Cookson MR. Alpha-synuclein and neuronal cell death. Mol Neurodegener. 2009;4:9.
   PubMed Web of Science ®Google Scholar
• Lucking CB, Dürr A, Bonifati V et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med. 2000;342:1560–1567.
   PubMed Web of Science ®Google Scholar
• Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25:302–305.
   PubMed Web of Science ®Google Scholar
• Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183:795–803.
   PubMed Web of Science ®Google Scholar
• Klein C, Grunewald A, Hedrich K. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology. 2006;66:1129–1130.
   Web of Science ®Google Scholar
• Yao Z, Wood NW. Cell death pathways in Parkinson’s disease: role of mitochondria. Antioxid Redox Signal. 2009;11:2135–2149.
   PubMed Web of Science ®Google Scholar
• Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010;8:e1000298.
   PubMed Web of Science ®Google Scholar
• Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, Singleton AB. Comprehensive analysis of LRRK2 in publicly available Parkinson’s disease cases and neurologically normal controls. Hum Mutat. 2008;29:485–490.
   PubMed Web of Science ®Google Scholar
• Daniels V Baekelandt V Taymans JM. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies. Neurosignals. 2011;19:1–15.
   Google Scholar